Pharmaceuticals, Biotechnology and Life Sciences
Funding for tuberculosis research fell $1.3 billion short of global targets last year, threatening worldwide goals to eliminate the disease between 2030 and 2035, researchers said on Monday.
Velneva’s Clostridium difficile vaccine Candidate meets Phase II trial target
Horizon Pharma and its affiliate, Horizon Therapeutics, has gotten the European Commission’s (EC’s) approval for Ravicti – glycerol phenylbutyrate – Oral Liquid for use as an adjunctive therapy for chronic management patients with six subtypes of Urea Cycle Disorders (UCDs).
Boston-based PureTech Health plc has launched a Scientific Advisory Board (SAB) of distinguished scientists and physicians, and the expansion of PureTech’s senior team.
By Pamela Barbaglia, Olivia Oran and Arno Schuetze LONDON/NEW YORK/FRANKFURT (Reuters) – Investment bank Lazard is working with Sanofi’s management…
Two-decade Pfizer mission pays off for Gueggenheim’s deal king
Impax Laboratories has been granted by the European Commission (EC) authorization to market its Numient oral capsule formulation for the symptomatic treatment of adult patients with Parkinson’s disease.
Kiadis Pharma did not generate any revenues in the first nine months of 2015, the company said Friday.
The World Health Organisation (WHO) said on Thursday that in 2014 it had recorded the highest number of new HIV cases in its European Region, which also includes Central Asia, since the start of reporting in the 1980s.
Sinclair IS Pharma plc will sell its non-aesthetics business to Alliance Pharma plc for £132m